In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.

I believe we are about to do it again with this new AI project called Stargate

Jennifer Jarrett net worth and biography

Jennifer Jarrett Biography and Net Worth

COO of Arcus Biosciences

Jennifer Jarrett serves as Chief Operating Officer, Director of the Company. Ms. Jarrett currently serves as Vice President, Corporate Development and Capital Markets at Uber, Inc. Ms. Jarrett served as our Chief Operating and Financial Officer from June 2018 to January 2019, and as our Chief Business Officer and Chief Financial Officer from March 2017 to June 2018. From April 2016 to September 2016, Ms. Jarrett was the Chief Financial Officer of Medivation, Inc., a biopharmaceutical company, which was acquired by Pfizer Inc. Prior to that, Ms. Jarrett spent 20 years in investment banking, most recently as Managing Director at Citigroup from July 2010 to April 2016, where she was responsible for managing their west coast life sciences investment banking practice. Before that, Ms. Jarrett was a Director and Managing Director at Credit Suisse from 2000 to 2010, and an associate at Donaldson, Lufkin & Jenrette from 1998 to 2000. During her tenure as an investment banker, Ms. Jarrett covered biotechnology and pharmaceutical companies, primarily in the San Francisco Bay Area. She currently serves on the board of directors of Arena Pharmaceuticals, Inc. and Syndax Pharmaceuticals, Inc., and previously served on the board of Audentes Therapeutics until its acquisition by Astellas Pharma Inc. in January 2020. Ms. Jarrett holds a B.A. in Economics, cum laude, from Dartmouth College and an M.B.A. from Stanford Graduate School of Business.

What is Jennifer Jarrett's net worth?: The estimated net worth of Jennifer Jarrett is at least $3.54 million as of March 27th, 2024. Ms. Jarrett owns 215,253 shares of Arcus Biosciences stock worth more than $3,536,607 as of November 14th. This net worth approximation does not reflect any other assets that Ms. Jarrett may own. Additionally, Ms. Jarrett receives a salary of $925,290.00 as COO at Arcus Biosciences. Learn More about Jennifer Jarrett's net worth.
How old is Jennifer Jarrett?: Ms. Jarrett is currently 53 years old. There are 6 older executives and no younger executives at Arcus Biosciences. The oldest executive at Arcus Biosciences is Dr. Juan Carlos Jaen Ph.D., Co- Founder & President, who is 66 years old. Learn More on Jennifer Jarrett's age.
What is Jennifer Jarrett's salary?: As the COO of Arcus Biosciences, Inc., Ms. Jarrett earns $925,290.00 per year. The highest earning executive at Arcus Biosciences is Dr. Juan Carlos Jaen Ph.D., Co- Founder & President, who commands a salary of $931,140.00 per year. Learn More on Jennifer Jarrett's salary.
How do I contact Jennifer Jarrett?: The corporate mailing address for Ms. Jarrett and other Arcus Biosciences executives is 3928 Point Eden Way, Hayward CA, 94545. Arcus Biosciences can also be reached via phone at (510) 694-6200 and via email at [email protected]. Learn More on Jennifer Jarrett's contact information.
Has Jennifer Jarrett been buying or selling shares of Arcus Biosciences?: Jennifer Jarrett has not been actively trading shares of Arcus Biosciences within the last three months. Most recently, Jennifer Jarrett sold 11,551 shares of the business's stock in a transaction on Wednesday, March 27th. The shares were sold at an average price of $17.55, for a transaction totalling $202,720.05. Following the completion of the sale, the chief operating officer now directly owns 215,253 shares of the company's stock, valued at $3,777,690.15. Learn More on Jennifer Jarrett's trading history.
Who are Arcus Biosciences' active insiders?: Arcus Biosciences' insider roster includes Robert Goeltz II (CFO), Juan Jaen (President), Jennifer Jarrett (COO), Terry Rosen (CEO), and Carolyn Tang (General Counsel). Learn More on Arcus Biosciences' active insiders.
Are insiders buying or selling shares of Arcus Biosciences?: During the last twelve months, Arcus Biosciences insiders bought shares 1 times. They purchased a total of 15,238,095 shares worth more than $319,999,995.00. During the last twelve months, insiders at the sold shares 7 times. They sold a total of 83,955 shares worth more than $1,577,199.69. The most recent insider tranaction occured on March, 27th when COO Jennifer Jarrett sold 11,551 shares worth more than $202,720.05. Insiders at Arcus Biosciences own 12.3% of the company. Learn More about insider trades at Arcus Biosciences.
Information on this page was last updated on 3/27/2024.

Jennifer Jarrett Insider Trading History at Arcus Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/27/2024	Sell	11,551	$17.55	$202,720.05	215,253
3/18/2024	Sell	13,449	$17.92	$241,006.08	226,804
2/26/2024	Sell	24,555	$20.07	$492,818.85	274,323
12/22/2023	Sell	21,521	$17.76	$382,212.96	258,878
9/22/2023	Sell	21,369	$19.99	$427,166.31	302,691
7/28/2023	Sell	45,000	$20.25	$911,250.00	336,566
6/22/2023	Sell	12,437	$19.12	$237,795.44	381,566
6/16/2023	Sell	12,563	$19.35	$243,094.05	394,003
3/16/2023	Sell	8,729	$16.81	$146,734.49	406,217
1/26/2023	Sell	300	$23.56	$7,068.00	416,546
12/16/2022	Sell	16,482	$30.75	$506,821.50	147,609
9/16/2022	Sell	12,677	$26.28	$333,151.56	130,942
6/16/2022	Sell	6,081	$20.72	$125,998.32	125,233
3/16/2022	Sell	9,617	$31.62	$304,089.54
12/20/2021	Sell	34,822	$41.48	$1,444,416.56
12/16/2021	Sell	5,560	$39.82	$221,399.20
9/20/2021	Sell	30,634	$35.18	$1,077,704.12
6/4/2021	Sell	1,044	$24.91	$26,006.04
3/16/2021	Sell	8,661	$35.03	$303,394.83	116,973

Jennifer Jarrett Buying and Selling Activity at Arcus Biosciences

Arcus Biosciences Company Overview

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

Today's Range

Now: $16.04

$15.83

$16.48

50 Day Range

MA: $16.63

$15.28

$18.44

2 Week Range

Now: $16.04

$13.49

$20.31

Volume

39,307 shs

Average Volume

732,875 shs

Market Capitalization

$1.47 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.89

Trump won. Buy this coin now.

From Weiss Ratings | Ad

Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.

This could be his favorite coin.

Jennifer Jarrett Biography and Net Worth

What is Jennifer Jarrett's net worth?

How old is Jennifer Jarrett?

What is Jennifer Jarrett's salary?

How do I contact Jennifer Jarrett?

Has Jennifer Jarrett been buying or selling shares of Arcus Biosciences?

Who are Arcus Biosciences' active insiders?

Are insiders buying or selling shares of Arcus Biosciences?